Quantum-Si Enters Sales Agreement with Leerink Partners

Quantum-Si ( (QSI) ) has shared an announcement.

On September 26, 2025, Quantum-Si Incorporated entered into a Sales Agreement with Leerink Partners LLC to potentially offer and sell up to $100 million of its Class A common stock. The agreement allows for sales at the company’s discretion and is contingent upon the effectiveness of a shelf registration statement filed with the SEC. The arrangement provides flexibility in stock sales, with Leerink Partners acting as sales agent, and includes provisions for commissions and legal expense reimbursements. This strategic move could impact Quantum-Si’s market presence and financial strategy, although the company is not obligated to sell any shares.

The most recent analyst rating on (QSI) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Quantum-Si stock, see the QSI Stock Forecast page.

Spark’s Take on QSI Stock

According to Spark, TipRanks’ AI Analyst, QSI is a Neutral.

Quantum-Si’s overall stock score reflects its challenging financial performance, with consistent losses and negative cash flows being the most significant factor. While technical indicators show some bullish momentum, the stock is overbought, and valuation metrics are weak due to ongoing losses. The earnings call highlights strategic initiatives and a strong cash position, but revenue challenges and lack of guidance weigh on the outlook.

To see Spark’s full report on QSI stock, click here.

More about Quantum-Si

Quantum-Si Incorporated operates in the biotechnology industry, focusing on the development of next-generation protein sequencing technology. The company aims to revolutionize the field of proteomics with its innovative products and services.

Average Trading Volume: 8,320,163

Technical Sentiment Signal: Sell

Current Market Cap: $301.7M

Find detailed analytics on QSI stock on TipRanks’ Stock Analysis page.